Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IIT2017-03-Merin-HaploBFR: Bendamustine, Fludarabine, and Rituximab Conditioning for Haploidentical Stem Cell Transplantation with CD56-Enriched Donor Cell Infusion for Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL

NCT03524235 is registered in ClinicalTrials.gov with Noah Merin as lead sponsor.

NCT NCT03524235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03524235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IIT2017-03-Merin-HaploBFR: Bendamustine, Fludarabine, and Rituximab Conditioning for Haploidentical Stem Cell Transplantation with CD56-Enriched Donor Cell Infusion for Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL
Lead sponsor
Noah Merin
Phase
Phase 1
Overall status
Completed
Start date
July 18, 2018
Completion date
November 6, 2024
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, cll, hodgkin lymphoma, lymphoma, multiple myeloma